MENU
TGTX
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
TG Therapeutics (TGTX) Ownership - Who owns TG Therapeutics?
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases... Show more
Industry: #Biotechnology
Profile
Industry
Biotechnology
Address
3020 Carrington Mill boulevard
Phone
+1 212 554-4484
Employees
264
Web
https://www.tgtherapeutics.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
5.86B
P/E Ratio
249.00
Total Cash
311M
Projected Growth
N/A
Total Debt
253.72M
Revenue
329M
Risk (Beta)
2.52
Dividend Yield
N/A
Total Cash/Share
1.98
Total Debt/Equity
0.21
Revenue/Share
2.05 USD as % of share price
Fundamentals
TGTX
Capitalization
5.86B
P/E Ratio
249.00
Risk (Beta)
2.52
Dividend Yield
N/A
Total Cash
311M
Total Cash/Share
1.98
Total Debt
254M
Total Debt/Equity
0.21
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
2.05%
Revenue
329M
ROE
N/A
Book Value
222M
P/B Ratio
26.39
Cash Flow
N/A
Earnings
0.16
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
156K
Current Ratio
6.25
Current Revenue Per Employee
320073.97
Dividends Per Share - Security
N/A
EBITDA
49.9M
Float
N/A
Float - Current
N/A
Gross Income Margin
85.77
Revenue To Assets
5.15
Shares Held By Institutions
4.61B
Shares Outstanding - Current
157M
Total Liabilities
355M
Total Volume MTD
N/A
Value
-1
Gain YTD
24.086
View a ticker or compare two or three
VS
VS
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a biopharmaceutical company
Industry Biotechnology
Profile
Fundamentals
Details
Industry
Biotechnology
Address
3020 Carrington Mill boulevard
Phone
+1 212 554-4484
Employees
264
Web
https://www.tgtherapeutics.com